Loading...
NPI 1427657360 · Jenks, OK · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Chrom Medical Labs is a clinical medical laboratory provider located in Jenks, Oklahoma. This profile covers 21 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Chrom Medical Labs |
| Address | 201 W Main St Ste 101a |
| City | Jenks |
| State | OK |
| ZIP | 74037 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 21, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.4M |
| Medicaid | $280 |
CHROM MEDICAL LABS is a clinical medical laboratory with an NPI enumerated on 2020-10-21 (~6 years ago), indicating it has been active in Medicare/Medicaid billing for several years and is an established entrant in the laboratory testing market. The tenure supports interpretation of recurring testing lines rather than a one-off billing pattern.
Medicare dominates this provider’s public-payer footprint: total Medicare revenue is $4.4M versus total Medicaid revenue of $283, so the provider is effectively single-payer at scale with Medicare representing virtually all reported public-payer receipts. Medicaid billing is de minimis in dollar terms and does not materially contribute to the provider’s revenue mix.
Revenue concentration in Medicare is extreme: the precomputed top 3 Medicare codes account for 96.4% of total Medicare revenue, indicating the business is highly focused on a small set of high-volume or high-value tests rather than a broad lab portfolio. This concentration creates exposure to utilization or reimbursement changes for those few codes.
The provider’s Medicare revenue is overwhelmingly driven by K1034, which accounts for $4.2M and 93.2% of the provider’s Medicare revenue, reflecting massive volume in nonprescription self-administered COVID-19 test provision. This mix implies core operations are oriented to high-throughput COVID-19 diagnostic test fulfillment rather than routine clinical genetics or specialty pathology as the primary revenue source.
CHROM MEDICAL LABS is an extreme national outlier on K1034: it ranks #101 of 30143 providers nationally and is labeled an "extreme outlier, far above typical national volume for this code." That ranking establishes the provider as a dominant national volume participant specifically for nonprescription self-administered COVID-19 tests, well above typical lab peers for that code.
Beyond K1034, the remaining Medicare top codes are largely specialty genetic testing (81419, 81185, 81325, 81302, etc.) that together make up a small share of Medicare revenue (the other top two codes in the top-3 precompute contribute to the 96.4% aggregate). These CPTs indicate the lab also performs targeted genomic and sequence analysis services, but at much lower volume and more typical national ranks (e.g., 81419 ranks #20 of 27).
Medicaid activity is narrowly concentrated: the single Medicaid code reported is K1034 with 479 claims and $479 revenue, representing 100.0% of Medicaid revenue and ranking #3 of 4 in-state (33th percentile). This shows the provider offers the same COVID-19 self-test product to Medicaid enrollees but at trivial Medicaid revenue levels compared with Medicare.
Competitive positioning differs by payer and code: for K1034 the provider is a clear national-volume leader on Medicare (extreme outlier), while for genetic CPTs the provider’s ranks are mid-to-lower among small national peer sets (generally in the 19th–40th percentile range), consistent with a modest, typical participant in specialty genetic testing. The Medicaid rank (3 of 4, 33th percentile) indicates modest in-state standing for the same COVID-19 test.
Operational implication: the firm appears to operate as a high-volume COVID-19 self-test fulfillment or distribution operation layered with a smaller specialty molecular/genetic testing capability. Payers and network managers should treat the entity primarily as a concentrated COVID-19 testing supplier for Medicare beneficiaries, with ancillary genomic testing lines that are not primary revenue drivers.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 348,390 | $10 | $4.2M |
| 81419 | The lab analyst performs the technical lab test on a specimen such as blood to conduct a genomic sequence analysis panel. The test evaluates the genetic sequences of at least the 24 genes listed in… | 40 | $2,400 | $105.6K |
| 81185 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the calcium voltage–gated channel subunit alpha1 A gene, also called CACNA1A. | 50 | $830 | $37.3K |
| 81325 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the peripheral myelin protein 22, or PMP22, gene. | 50 | $750 | $36.9K |
| 81302 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the methyl CpG binding protein 2, or MECP2 gene. | 50 | $520 | $24.8K |
| 81189 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the cystatin B gene (CSTB). | 50 | $270 | $13.2K |
| 81309 | The lab analyst performs the technical lab test to analyze specific gene sequences of the phosphatidylinositol–4, 5–biphosphate 3–kinase, catalytic subunit alpha (PIK3CA) gene. | 50 | $270 | $13.2K |
| 81286 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the frataxin gene (FXN). | 40 | $270 | $10.5K |
| 81191 | The lab analyst performs the technical lab test using a specimen such as formalin–fixed paraffin embedded tissue (FFPE) to analyze NTRK1 (neurotrophic receptor tyrosine kinase 1) translocations that… | 50 | $200 | $9.9K |
| 81192 | The lab analyst performs the technical lab test using a specimen such as formalin–fixed paraffin embedded tissue (FFPE) to analyze NTRK2 (neurotrophic receptor tyrosine kinase 2) translocations that… | 50 | $200 | $9.9K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81419 | 3 | 10 | 150 | $2,400 | $427.1K |
| K1034 | 3 | 330 | 260 | $10 | $123.3K |
| 81185 | 3 | 10 | 70 | $830 | $81.8K |
| 81302 | 3 | 10 | 180 | $520 | $75.9K |
| 81325 | 3 | 10 | 50 | $760 | $71.9K |
| 81189 | 3 | 10 | 110 | $270 | $30.3K |
| 81309 | 3 | 10 | 70 | $270 | $27.2K |
| 81286 | 2 | 10 | 40 | $270 | $23.1K |
| 81191 | 2 | 10 | 50 | $200 | $16.6K |
| 81192 | 2 | 10 | 50 | $200 | $16.6K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 480 | $1 | $480 |
How this provider's Medicaid billing volume and revenue compare to other Oklahoma providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Oklahoma median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 3 | 10 | 740 | $1 | $210 |
Other providers in the same ZIP code as Chrom Medical Labs, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Speech And Beyond, LLC | OK | Speech-Language Pathologist | $0 | $6.3M |
| Lewis & Wakefield, PLLC | OK | Family Medicine Physician | $0 | $2.8M |
| Mco Peds PLLC | OK | General Practice Dentistry | $0 | $2.5M |
| Andrew Donnelly | OK | Family Medicine Physician | $471.7K | $0 |
| Sandeep Bhatia | OK | Ophthalmology Physician | $202.4K | $173.3K |
| Michael Chamberlain | OK | Ophthalmology Physician | $285.5K | $0 |
| Brian Lewis | OK | Family Medicine Physician | $243.9K | $0 |
| Jason Ellen | OK | Optometrist | $182.3K | $0 |
| Brandon Hadel | OK | Optometrist | $99.9K | $0 |
| Patrick Branagan | OK | Primary Podiatric Medicine Podiatrist | $94.3K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.